October 8, 2010 – Siemens PETNET Solutions has expanded its imaging biomarker capabilities in Nottingham, England and can now produce new biomarkers as investigational medicine products (IMP) in the United Kingdom.
The IMPs include a hypoxic agent that can identify tumor tissues with low oxygen supply and an amyloid agent for PET imaging of ß-amyloid deposits in the brain.
For more information: www.siemens.com/healthcare
Editor's Note: This article has been updated to correct an earlier version. Oct. 15, 2026 — GE HealthCare has announced ...
October 16, 2026 
Oct. 12, 2026 — RWJBarnabas Health and Rutgers Cancer Institute have earned a systemwide accreditation from the American ...
October 13, 2026 
Oct. 5, 2026 — GE HealthCare has announced a definitive agreement to acquire SOFIE Biosciences, a U.S.-based CMO for PET ...
October 06, 2026 
Sept. 22, 2026 — Researchers from the Keck School of Medicine of USC are developing a new “plug-and-play” platform that ...
September 23, 2026 
Sept. 1, 2026 — On Sept. 24, 2026 at 1 p.m. EDT, Siemens Healthineers will present a webinar on "Advancing Women's ...
September 03, 2026 